BridgeMD
New treatment option for Autosomal Dominant Spinocerebellar Ataxia (SCA1, 2,3,6,7,27B)
Official title Autosomal Dominant Spinocerebellar Ataxias and Social Cognition
ClinicalTrials.gov ID: NCT07099651
What this study is testing
- What it's testing
- Spinocerebellar ataxias are a group of rare neurodegenerative diseases, clinically and genetically highly heterogeneous, with an estimated mean prevalence of 2.7 per 100,000 population. The term "spinocerebellar ataxia" or "SCA" is often used for ataxias of genetic origin of autosomal dominant transmission, which are the subject of this study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 100. Healthy volunteers may be eligible.
You may be able to join if
- For all participants:
- Men or women aged 18 and over
- At least 7 years' schooling (CEP level)
- Ability to read, write and speak French
- Signed informed consent to participate in the study For patients : \- With molecularly confirmed autosomal dominant spinocerebellar ataxia (SCA1, 2...
You likely can't join if
- For patients and controls:
- Simultaneous participation in another protocol that may interfere with the measurement of the criteria of interest
- Physical or cultural factors likely to interfere with test performance
- History likely to interfere with cognition (stroke, cranioencephalic trauma, other neurodegenerative disease, epilepsy, learning disability, alcohol...
- Persons with contraindications to MRI scans
- Pregnant, nursing or parturient women
See the full eligibility criteria
- For all participants:
- Men or women aged 18 and over
- At least 7 years' schooling (CEP level)
- Ability to read, write and speak French
- Signed informed consent to participate in the study For patients : \- With molecularly confirmed autosomal dominant spinocerebellar ataxia (SCA1, 2, 3, 6, 7, 27B) For controls: \- With no neurological pathology...
- For patients and controls:
- Simultaneous participation in another protocol that may interfere with the measurement of the criteria of interest
- Physical or cultural factors likely to interfere with test performance
- History likely to interfere with cognition (stroke, cranioencephalic trauma, other neurodegenerative disease, epilepsy, learning disability, alcohol dependence syndrome, psychiatric disorders...)
- Persons with contraindications to MRI scans
- Pregnant, nursing or parturient women
- Persons deprived of their liberty by judicial or administrative decision
- Persons under compulsory psychiatric care
- Persons subject to a legal protection measure
- Persons unable to express their consent
- Persons not affiliated to or not benefiting from a social security scheme (beneficiary or beneficiary entitled)
The study team makes the final eligibility decision.
Where it's taking place
- Angers, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 100 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Angers, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.